Schilke Tobin

Schilke Tobin is listed in filings as Chief Financial Officer at Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX). This profile follows SEC Form 4 activity through Mar 4, 2026, including sale activity. Recent filings connect the profile to Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) (CRNX) and Revance Therapeutics, Inc. - Common Stock (RVNC). The current snapshot covers public activity from Jul 2, 2024 to Mar 4, 2026. Reported amounts are shown as $266.3K to $2.7M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.